Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Not Confirmed
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Not Confirmed
Not Confirmed
03-05 January, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
17-20 March, 2025
Antibody EngineeringAntibody Engineering
Industry Trade Show
Not Confirmed
15-19 December, 2024
Pharma, Lab & Chemical...Pharma, Lab & Chemical Expo
Industry Trade Show
Not Confirmed
03-05 January, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions
30 Oct 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/sparx-biopharmaceutical-announces-fda-greenlight-for-ind-application-of-spx-303-a-first-in-human-anti-lilrb2pd-l1-antibody-drug-301971522.html
Details:
SPX-303 is a bispecific antibody therapy targeting LILRB2 and PD-L1, under investigation for various solid tumors treatment.
Lead Product(s): SPX-303
Therapeutic Area: Oncology Brand Name: SPX-303
Study Phase: Phase IProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 11, 2024
SparX Doses First Patient with SPX-303, an anti-LILRB2/PD-L1 Bispecific Antibody
Details : SPX-303 is a bispecific antibody therapy targeting LILRB2 and PD-L1, under investigation for various solid tumors treatment.
Brand Name : SPX-303
Molecule Type : Large molecule
Upfront Cash : Not Applicable
April 11, 2024
Details:
SPX-303 is a First-in-Its Class bispecific antibody therapy, ingeniously engineered to engage two cardinal immune checkpoint proteins, LILRB2 and PD-L1, simultaneously.
Lead Product(s): SPX-303
Therapeutic Area: Oncology Brand Name: SPX-303
Study Phase: IND EnablingProduct Type: Large molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2023
Lead Product(s) : SPX-303
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : SPX-303 is a First-in-Its Class bispecific antibody therapy, ingeniously engineered to engage two cardinal immune checkpoint proteins, LILRB2 and PD-L1, simultaneously.
Brand Name : SPX-303
Molecule Type : Large molecule
Upfront Cash : Not Applicable
October 30, 2023
Details:
The collaboration aims for the utilization of SPX-101, an innovative monoclonal antibody (mAb) that targets the Claudin 18.2 (CLDN18.2) tumor specific antigen, as an exciting component in Arovella's CLDN18.2-CAR-iNKT cells as a leading off-the-shelf CAR-iNKT cell therapy.
Lead Product(s): SPX-101
Therapeutic Area: Oncology Brand Name: SPX-101
Study Phase: PreclinicalProduct Type: Large molecule
Sponsor: Arovella Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 10, 2023
Lead Product(s) : SPX-101
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Arovella Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims for the utilization of SPX-101, an innovative monoclonal antibody (mAb) that targets the Claudin 18.2 (CLDN18.2) tumor specific antigen, as an exciting component in Arovella's CLDN18.2-CAR-iNKT cells as a leading off-the-shelf CAR-...
Brand Name : SPX-101
Molecule Type : Large molecule
Upfront Cash : Undisclosed
October 10, 2023
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?